, Columnist
Repatha Will Test the New Drug Pricing Reality
Strong heart-attack data could give the drugmaker an edge on payers.
This article is for subscribers only.
The epic battle between drug makers and the insurers and pharmacy benefit managers that pay for their medicines just opened a fascinating new front.
Amgen Inc.'s earnings report Thursday afternoon was largely overshadowed by its announcement that its cholesterol-lowering drug Repatha succeeded in a clinical trial designed to prove it helps prevent heart attacks and other cardiovascular events.